
OS Therapies fell 56.9% from $1.73 to $0.74, behind the S&P 500's +11.0%. Its worst day was Jun 30 (−15.2%), and its low came Nov 16 at $0.68.
Story events cover the past 12 months · Times ET
Nov 18, 2025 – Nov 17, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
EPS of $-0.41 missed the $-0.16 estimate on $0.00 revenue.
+6.0% · S&P 500 +2.9%
OS Therapies shares rose 22.1%, while the S&P 500 rose 0.8%.
+22.1%, the year's best day · S&P 500 +0.8%
EPS of $-0.27 missed the $-0.19 estimate on $0.00 revenue (est. $242,750.00).
−8.0% · S&P 500 −0.1%
OS Therapies shares fell 12.6%, while the S&P 500 rose 0.3%.
−12.6% · S&P 500 +0.3%
OS Therapies closed at its highest level of the year, 29.5% above where the year started.
+19.1% · S&P 500 +1.6%
OS Therapies shares rose 17.8%, while the S&P 500 rose 0.8%.
+17.8% · S&P 500 +0.8%
EPS of $-0.20 beat the $-0.23 estimate on $0.00 revenue (est. $204,400.00).
−9.3% · S&P 500 −0.5%
Leading Clinical Stage Oncology Company Now Able to Complete CMMA Submission to U.K’s MHRA for Early Commercial Access and Trial Authorisation
−14.8% · S&P 500 −4.4%
Where it ended: a close of $0.74 on Nov 17, 2026. Up next: Q3 2026 earnings on Dec 1, 2026 (EPS est. $-0.12, revenue est. $600,000.00).
Nothing in the past 12 months.
All OSTX dividend history